12 Folgen

  1. S2 Episode 6: Is MDMA a Potential Treatment for Negative Symptoms of Schizophrenia? Exploring Stigma and Strategies to Alleviate Symptoms

    Vom: 20.7.2023

  2. S2 Episode 5: First-Episode Schizophrenia: The Importance of Engaging and Educating Patients and Their Families in Treatment

    Vom: 21.6.2023

  3. S2 Episode 4: Common and Commonly Unrecognized: Clinical High-risk Syndrome, Psychosis, and Schizophrenia

    Vom: 23.5.2023

  4. S2 Episode 3: Psychiatric Comorbidity in Schizophrenia: Assessing Patients and the Impact on Treatment Decisions and Outcomes

    Vom: 19.4.2023

  5. S2 Episode 2: Long-Acting Injectables and Schizophrenia: Mitigating the Risk for Relapse and Rehospitalization

    Vom: 22.3.2023

  6. S2 Episode 1: Treatment-Resistant Schizophrenia: Detection, Management, and the Importance of Early Initiation of Treatment

    Vom: 22.3.2023

  7. S1 Episode 6: Relapse in Schizophrenia: Why It Occurs, How Often It Occurs, and What We Can Do About It

    Vom: 7.12.2022

  8. S1 Episode 5: Neuroimaging in Schizophrenia: What Have We Learned?

    Vom: 9.11.2022

  9. S1 Episode 4: How Can We Assess Cognitive Functioning in Patients With Schizophrenia? And What Can We Do About It?

    Vom: 5.10.2022

  10. S1 Episode 3: What New Antipsychotic Drugs Are Available for Schizophrenia? What Drugs Are Under Development? And What Do They Potentially Offer?

    Vom: 13.9.2022

  11. S1 Episode 2: Antipsychotics in Schizophrenia: Effectiveness and Optimal Dosing

    Vom: 2.8.2022

  12. S1 Episode 1: What Are the Major Metabolic and Neurologic Risks Associated With Antipsychotic Medications?

    Vom: 2.8.2022

1 / 1

Listen to Medscape InDiscussion: Schizophrenia, a podcast series where thought leaders and clinical experts share their diverse insights and practical ideas for optimizing patient care. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984480). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Visit the podcast's native language site